LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for LENZ Therapeutics and ARS Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENZ Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
LENZ Therapeutics presently has a consensus price target of $23.00, suggesting a potential upside of 627.85%. ARS Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 520.35%. Given LENZ Therapeutics’ higher possible upside, research analysts plainly believe LENZ Therapeutics is more favorable than ARS Pharmaceuticals.
Volatility & Risk
LENZ Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
Profitability
This table compares LENZ Therapeutics and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENZ Therapeutics | -586.74% | -53.39% | -49.14% |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
Earnings & Valuation
This table compares LENZ Therapeutics and ARS Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENZ Therapeutics | $19.09 million | 5.20 | -$82.13 million | ($4.09) | -0.77 |
| ARS Pharmaceuticals | $84.28 million | 4.76 | -$171.30 million | ($2.18) | -1.85 |
LENZ Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
ARS Pharmaceuticals beats LENZ Therapeutics on 7 of the 13 factors compared between the two stocks.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
